Evidence map›Paper›PMID 41847134›Full record

ArticleFrontiers in pharmacology2026

Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer.

Jaqueline B Schuch, Mariana R Botton, Angélica C De Baumont, Giovana Curzel, Nathan A Cadore, Cláudia Bordignon, Mahira L Rosa, Vitor F Vasconcellos, Lilian A R Barros, Cristiano P Souza and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Jaqueline B Schuch *Hospital Moinhos de Vento, Porto Alegre, Brazil.
Mariana R Botton *Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Angélica C De BaumontHospital Moinhos de Vento, Porto Alegre, Brazil.
Giovana CurzelHospital Moinhos de Vento, Porto Alegre, Brazil.
Nathan A CadoreHospital Moinhos de Vento, Porto Alegre, Brazil.
Cláudia BordignonHospital Moinhos de Vento, Porto Alegre, Brazil.
Mahira L RosaHospital Moinhos de Vento, Porto Alegre, Brazil.
Vitor F VasconcellosHospital Universitário Cassiano Antônio Moraes, Vitória, Brazil.
Lilian A R BarrosInstituto Brasileiro de Controle do Câncer, São Paulo, Brazil.
Cristiano P SouzaHospital de Câncer de Barretos, Barretos, Brazil.
Williams F BarraNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil.
Daniela L C LouzeiroHospital de Oncologia Dr. Tarquinio Lopes Filho, São Luís, Brazil.
Alessandra NotariHospital Escola da Universidade Federal de Pelotas/Empresa Brasileira de Serviços Hospitalares (EBSERH), Pelotas, Brazil.
Juliana J de MenezesHospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Pedro E R LiedkeHospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Gláucio A BertolloAssociação Feminina de Educação e Combate ao Câncer (AFECC), Hospital Santa Rita de Cássia, Vitória, Brazil.
Aline B L GongoraHospital do Câncer UOPECCAN, Cascavel, Brazil.
Henrique G AscencoHospital Universitário Maria Aparecida Pedrossian, Campo Grande, Brazil.
Eduardo Kowalski-NetoHospital Calixto Midlej Filho, Santa Casa de Misericórdia de Itabuna, Itabuna, Brazil.
Christina P OppermannHospital Fêmina, Porto Alegre, Brazil.
Gustavo WerutskyHospital São Lucas PUCRS, Porto Alegre, Brazil.
Edilmar M SantosLiga Norte Riograndense Contra o Câncer, Natal, Brazil.
Flavio S BrandãoSanta Casa de Belo Horizonte, Belo Horizonte, Brazil.
Ruffo Freitas-JuniorHospital do Câncer Araújo Jorge da Associação de Combate ao Câncer em Goiás, Goiânia, Brazil.
Angélica Nogueira-RodriguesUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
André L C ManciniHospital Universitário Getúlio Vargas, Manaus, Brazil.
Marina BesselHospital Moinhos de Vento, Porto Alegre, Brazil.
Gabriel S MacedoHospital Moinhos de Vento, Porto Alegre, Brazil.
Daniela D RosaHospital Moinhos de Vento, Porto Alegre, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pharmacogenomic (PGx) variants can influence drug efficacy and safety, yet their prevalence in Latin American populations with cancer is underexplored. Our aim is to characterize the frequency and phenotypic distribution of actionable pharmacogenes in Brazilian patients with metastatic prostate cancer (MPC) and Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer (BC). Methods: This analysis included 452 patients (259 BC, 193 MPC) from a multicenter study across 19 Brazilian sites. Exome sequencing was performed, and PGx variants were analyzed using the Pharmacogenomics Clinical Annotation Tool (PharmCAT) following the Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines. Genotypes, star alleles, and predicted phenotypes were reported for 15 clinically relevant pharmacogenes. Results: Actionable PGx phenotypes were detected in 99.33% of participants. The decreased-function Conclusion: Nearly all Brazilian patients with cancer carried at least one actionable PGx variant, highlighting the potential impact of PGx-guided therapy in oncology. These results underscore the value of integrating pharmacogenomic strategies into clinical practice in Brazil.

Indexed as

breast neoplasmsexome sequencingpharmacogeneticspharmacogenomicsprostate neoplasms

Identifiers

PMID41847134
PMCPMC12989591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.